Tyra biosciences announces late-breaking poster presentation on tyra-300 preclinical results at endo 2025

Carlsbad, calif. , july 8, 2025 /prnewswire/ -- tyra biosciences, inc. (nasdaq: tyra), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in fibroblast growth factor receptor (fgfr) biology, announced today that a late-breaking abstract has been accepted for presentation at the endocrine society's annual meeting (endo 2025), taking place july 12-15, 2025 in san francisco, ca.
TYRA Ratings Summary
TYRA Quant Ranking